Research programme: tau protein degraders - Seed therapeutics
Latest Information Update: 13 Aug 2024
At a glance
- Originator Seed Therapeutics
- Class
- Mechanism of Action Tau protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 06 Aug 2024 SEED Therapeutics plans to file an IND application for Alzheimer’s disease in 2026
- 06 Aug 2024 Seed therapeutics plans preclinical trial for Alzheimer’s disease in 2025
- 27 Oct 2023 Early research in Neurodegenerative disorders in USA (unspecified route) (Seed therapeutics pipeline, October 2023)